15965-58-9 Usage
General Description
1H-Benzimidazole,2-chloro-4-methoxy is a chemical compound with the molecular formula C8H7ClN2O. It is a benzimidazole derivative with a chlorine atom at position 2 and a methoxy group at position 4 on the benzene ring. 1H-Benzimidazole,2-chloro-4-methoxy-(9CI) is used in organic synthesis and pharmaceutical research as a building block for the synthesis of various bioactive molecules. It has potential applications in the development of new drugs for the treatment of various diseases and medical conditions. 1H-Benzimidazole,2-chloro-4-methoxy-(9CI) may have biological activity and pharmacological properties that make it of interest for further study and exploration in medicinal chemistry. However, further research and testing are needed to fully understand its potential uses and effects.
Check Digit Verification of cas no
The CAS Registry Mumber 15965-58-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,5,9,6 and 5 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 15965-58:
(7*1)+(6*5)+(5*9)+(4*6)+(3*5)+(2*5)+(1*8)=139
139 % 10 = 9
So 15965-58-9 is a valid CAS Registry Number.
15965-58-9Relevant articles and documents
Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives
Ogino, Yoshio,Ohtake, Norikazu,Nagae, Yoshikazu,Matsuda, Kenji,Moriya, Minoru,Suga, Takuya,Ishikawa, Makoto,Kanesaka, Maki,Mitobe, Yuko,Ito, Junko,Kanno, Tetsuya,Ishihara, Akane,Iwaasa, Hisashi,Ohe, Tomoyuki,Kanatani, Akio,Fukami, Takehiro
scheme or table, p. 5010 - 5014 (2009/05/07)
Design, syntheses, and structure-activity relationships of a novel class of 2-{3-oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole NPY Y5 receptor antagonists are described. The benzimidazole structures were newly designed based on the urea linkage of our prototype Y5 receptor antagonists (2 and 3). By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k). Crown Copyright
